Gencebok

Gencebok is a biotechnology company focused on developing next-generation gene therapies using advanced viral vector technologies. The company was founded by Federico Mingozzi, the former Chief Scientific Officer of Spark Therapeutics, a pioneer in the gene therapy space. Gencebok aims to address the fundamental challenges of current Adeno-associated virus (AAV) delivery systems, including immunogenicity and limited tissue specificity. By engineering optimized capsids and expression cassettes, the company seeks to expand the reach of genetic medicines to a broader range of diseases and patient populations. Currently in the pre-clinical stage, Gencebok is leveraging its founders' deep expertise in translational science to build a robust pipeline of transformative treatments.